source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2022-07-10 11:00:00 | https://www.fool.com/investing/2022/07/10/how-to-earn-10000-a-year-in-passive-retirement-inc/ | You'll either need a decent chunk of change or some patience. | How to Earn $10,000 a Year in Passive Retirement Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-10 05:58:00 | https://www.fool.com/investing/2022/07/10/3-unstoppable-dividend-stocks-to-buy-and-never-sel/ | All three of these companies have strong underlying businesses and offer attractive dividends. | 3 Unstoppable Dividend Stocks to Buy and Never Sell | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-10 05:21:00 | https://www.fool.com/investing/2022/07/10/2-surefire-dividend-stocks-id-buy-now-and-hold-for/ | These dividend-paying stocks have reliable cash flows, but they've been beaten down to some very attractive prices. | 2 Surefire Dividend Stocks I'd Buy Now and Hold for at Least a Decade | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-09 07:00:00 | https://www.fool.com/investing/2022/07/09/abbvie-stock-bull-vs-bear/ | The stock is beating the bear market. | AbbVie Stock: Bull vs. Bear | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-07-08 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-host-second-quarter-2022-earnings-conference-call-301582507.html | NORTH CHICAGO, Ill. , July 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens. | AbbVie to Host Second-Quarter 2022 Earnings Conference Call | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-08 06:00:00 | https://www.fool.com/investing/2022/07/08/want-to-beat-the-bear-market-try-these-2-stocks/ | There's plenty of growth ahead for these companies. | Want to Beat the Bear Market? Try These 2 Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-07-08 05:00:15 | https://www.forbes.com/sites/greatspeculations/2022/07/08/whats-driving-abbvie-stock-higher/ | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. | What's Driving AbbVie Stock Higher? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-07-07 16:44:51 | https://seekingalpha.com/article/4522278-abbvie-investors-dont-have-too-much-to-fear-ahead-of-q2-earnings | AbbVie shares have been on a long bull run but experienced a slight wobble after Q1'22 earnings were announced. That is to do with the imminent patent expiry of its $20bn per annum selling drug Humira and doubts about replacements Skyrizi and Rinvoq's earning potential. | AbbVie: Investors Don't Have Too Much To Fear Ahead Of Q2 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-07-07 15:24:56 | https://www.youtube.com/watch?v=NA2D4vukqVY | Jared Holz, Oppenheimer healthcare equity strategist, joins 'Power Lunch' to discuss the possibility of M&A in the healthcare sector, if investors remain focused on the oncology side of healthcare businesses and more. | The direction of M&A in biotech is very, very vast, says Oppenheimer's Holz | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2022-07-07 14:02:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/senate-finance-report-says-abbvie-shifted-profit-overseas-cut-taxes-2022-07-07/ | Drugmaker AbbVie Inc generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday. | Senate Finance report says AbbVie shifted profit overseas to cut taxes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-07 06:39:16 | https://investorplace.com/2022/07/best-stocks-for-2022-abbv-stock/ | ABBV stock is one of the best choices you can make for 2022. Even though the company is losing its Humira patent soon, it isn't slowing down. | Best Stocks for 2022: AbbVie Is a Recession-Resistant Dividend King | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-07-05 09:23:56 | https://247wallst.com/investing/2022/07/05/we-are-in-a-recession-7-dividend-aristocrats-are-the-best-second-half-ideas/ | The second-quarter gross domestic product (GDP) is likely to end up being negative, as the latest data from the Atlanta Fed's GDPNow tracker predicts real GDP growth of −1.0% as of June 30, down from +0.3% on June 27. | We Are in a Recession: 7 Dividend Aristocrats Are the Best Second-Half Ideas | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-05 07:30:00 | https://www.fool.com/investing/2022/07/05/this-blockbuster-drug-from-abbvie-is-closer-to-ano/ | Rinvoq could be approved to treat patients in the European Union with ulcerative colitis. | This Blockbuster Drug from AbbVie Is Closer to Another Major Indication | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-04 08:56:56 | https://investorplace.com/best-dividend-stocks/ | Dividend stocks are only becoming more attractive as income becomes increasingly paramount. These seven equities pair dividends with safety. | 7 Dividend Stocks to Buy in July 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-02 05:57:00 | https://www.fool.com/investing/2022/07/02/3-stocks-you-can-buy-and-hold-for-decades/ | These companies are built to last. | 3 Stocks You Can Buy and Hold for Decades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-07-01 04:28:11 | https://seekingalpha.com/article/4521314-abbvie-buy-dividend-king-growing-income | Even with the current bear market, the S&P 500 index's current yield is too anemic to provide lifestyle stability for most income investors. AbbVie's 3.7% dividend yield is more than double that of the broader market. | AbbVie: Buy This Dividend King For A Growing Stream Of Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-29 10:05:09 | https://www.zacks.com/stock/news/1945563/is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now | Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-06-28 16:02:09 | https://www.gurufocus.com/news/1788072/investors-need-not-be-alarmed-by-drug-patent-expirations | Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax. | Investors Need Not Be Alarmed by Drug Patent Expirations | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-06-27 12:10:57 | https://investorplace.com/2022/06/abbv-stocks-healthy-yield-makes-it-a-high-conviction-holding/ | Between the dividend payouts and the potential price appreciation, ABBV stock could be a pharma-market winner in 2022. The post AbbVie Stock's Healthy Yield Makes it a High-Conviction Holding appeared first on InvestorPlace. | AbbVie Stock's Healthy Yield Makes it a High-Conviction Holding | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-27 06:13:00 | https://www.fool.com/investing/2022/06/27/is-abbvie-about-to-get-a-new-blockbuster-drug/ | AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira. | Is AbbVie About To Get A New Blockbuster Drug? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-26 05:57:00 | https://www.fool.com/investing/2022/06/26/3-top-dividend-stocks-generating-passive-income/ | These stocks offer attractive dividends that investors should be able to count on. | 3 Top Dividend Stocks for Generating Passive Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-23 11:07:00 | https://www.fool.com/investing/2022/06/23/got-1000-buy-these-2-ultra-high-yield-dividend-sto/ | A top retailer and a pharmaceutical giant both now boast dividends that yield more than 3%. | Got $1,000? Buy These 2 Ultra-High-Yield Dividend Stocks on the Dip | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-06-22 12:15:00 | https://stockmarket.com/featured/what-stocks-to-invest-today-3-pharmaceutical-stocks-to-watch-2022-06-22 | Could these pharmaceutical stocks be worth watching today? | What Stocks to Invest Today? 3 Pharmaceutical Stocks To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-22 11:35:05 | https://www.zacks.com/stock/news/1942347/abbvie-abbv-files-qulipta-snda-for-chronic-migraine-prevention | With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication. | AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-20 11:39:10 | https://www.zacks.com/stock/news/1941163/abbvie-s-abbv-skyrizi-gets-fda-nod-for-crohn-s-disease | The FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was supported by data from two phase III induction studies - ADVANCE, MOTIVATE, and one maintenance study - FORTIFY. | AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-18 11:00:00 | https://www.fool.com/investing/2022/06/18/3-dividend-stocks-to-double-up-on-right-now/ | They're profitable, growing, hiking their payouts, and surviving the bear market without breaking a sweat. | 3 Dividend Stocks to Double Up on Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-16 10:49:52 | https://www.zacks.com/stock/news/1939723/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know | Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-06-14 12:24:58 | https://www.gurufocus.com/news/1758002/3-dividendpaying-stocks-vastly-outperforming-the-sp-500 | With many investors focusing on the decline in the S&P 500, you might be surprised to know there are companies that are greatly outperforming the index. In some cases, certain stocks have seen a total return that is more than 20% ahead of the benchmark's return year to date. | 3 Dividend-Paying Stocks Vastly Outperforming the S&P 500 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2022-06-13 15:42:35 | https://invezz.com/news/2022/06/13/spx-now-in-bear-market-territory-these-two-stocks-are-still-a-buy/ | The S&P 500 index down more than 20% for the year is an opportunity to position your long-term portfolio for remarkable profits, says the Chief Investment Officer of Pivotal Advisors. Reason to stay in the market right now Tiffany McGhee quoted historical data to explain why now is an opportunistic time for the long-te... | SPX now in bear market territory: these two stocks are still a buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-06-13 12:11:11 | https://investorplace.com/2022/06/consistent-clinical-results-indicate-upside-for-abbv-stock/ | ABBV stock can move higher as it trades at a very reasonable valuation. Meanwhile, AbbVie's financials and dividend payments sweeten the deal. | Consistent Clinical Results Indicate Upside for AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-06-13 07:31:42 | https://247wallst.com/investing/2022/06/13/7-strong-buy-dividend-kings-to-own-now-if-the-fed-rate-increase-this-week-is-huge/ | One thing has become painfully obvious, after Friday's consumer price index reading came in at a scorching 8.6% year over year, the highest reading since 1981. | 7 ‘Strong Buy' Dividend Kings to Own Now If the Fed Rate Increase This Week Is Huge | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-13 01:32:04 | https://seekingalpha.com/article/4517997-abbvie-not-perfect-largely-recession-proof | AbbVie could report extremely high growth rates for revenue and earnings per share since 2013. While analysts are rather pessimistic, management is expecting high-single-digit growth rates after 2025. | AbbVie: Not Perfect, But Largely Recession-Proof | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-06-12 08:56:44 | https://stockmarket.com/featured/top-biotech-stocks-to-invest-in-today-3-to-watch-this-week-2022-06-12 | Should investors be keeping an eye on these movers in the biotech space? | Top Biotech Stocks To Invest In Today? 3 To Watch This Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-06-11 06:43:20 | https://investorplace.com/2022/06/7-dividend-stocks-to-buy-for-your-grandkids/ | If this roiling market is making you seasick, then it's an excellent time batten down the hatches with these reliable dividend stocks. The post 7 Dividend Stocks to Buy for Your Grandkids appeared first on InvestorPlace. | 7 Dividend Stocks to Buy for Your Grandkids | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-10 09:00:00 | https://seekingalpha.com/article/4517622-abbvie-stock-highly-uncertain-future-not-yet-priced-in | AbbVie has generated outstanding returns for shareholders while paying out a hefty dividend that has been growing rapidly. Much of this success was due to the wildly profitable best-selling drug Humira. | AbbVie: Highly Uncertain Future Not Yet Priced In | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-10 07:53:22 | https://seekingalpha.com/article/4517668-abbvie-pfizer-market-maker-hedging-near-cap-gain | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. Institutions hold 71% of shares, insiders less than 1%, and dividends yield some 4% yearly. Prior price range forecasts at today's reward/risk ratios averaged +1% yearly rate of capital gains. | AbbVie Or Pfizer: Market-Maker Hedging Tells Best Near Cap Gain | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-06-10 07:04:39 | https://seekingalpha.com/article/4517662-abbvie-own-dividend-growth-portfolio | Shares of AbbVie have been performing well over the last decade as the company grew both sales and EPS. AbbVie shares are not expensive at the moment and the company has significant growth opportunities. | You Should Own AbbVie In Your Dividend Growth Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-06-10 06:11:09 | https://investorplace.com/2022/06/3-dividend-stocks-to-buy-now-for-20-years-of-income-growth/ | Investors looking for passive income from holding stocks should consider these dividend stocks that offer strong payouts. The post 3 Dividend Stocks to Buy Now for 20 Years of Income Growth appeared first on InvestorPlace. | 3 Dividend Stocks to Buy Now for 20 Years of Income Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-08 07:45:00 | https://www.fool.com/investing/2022/06/08/could-abbvie-stock-help-you-retire-a-millionaire/ | As long as you're not in a hurry, yes. | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-07 11:45:00 | https://www.fool.com/investing/2022/06/07/warren-buffett-just-sold-this-popular-stock-should/ | It probably wasn't a very good fit for his investing preferences in the first place. | Warren Buffett Just Sold This Popular Stock -- Should You? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-07 11:00:00 | https://www.fool.com/investing/2022/06/07/heres-what-this-drug-news-could-mean-for-abbvie/ | AbbVie recently shared encouraging clinical trial results for patients taking Rinvoq to treat Crohn's disease. | Here's What This Drug News Could Mean for AbbVie's Shareholders | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-06-06 15:56:45 | https://www.gurufocus.com/news/1745044/if-bigger-is-better-abbvie-stock-will-continue-to-climb | Bigger is not always better, but it does not hurt. | If Bigger Is Better, AbbVie Stock Will Continue to Climb | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-06-06 15:40:15 | https://www.youtube.com/watch?v=SqzB2lTMjbw | Christopher Raymond, Piper Sander senior biotech analyst, joins 'Power Lunch' to discuss what it means for biotech companies to be defensive, Raymond's thoughts around Abbvie and if biotech companies have hit a bottom. | AbbVie is the preeminent large-cap name in biotech, says Piper Sandler's Raymond | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-06-06 10:56:54 | https://www.youtube.com/watch?v=Bhv3wxSbEJM | Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to discuss the top drug trial data coming out of the American Society of Clinical Oncology conference in Chicago. | Dr. Scott Gottlieb on promising new cancer drug data: 'The future is here' | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-06-06 09:37:08 | https://247wallst.com/investing/2022/06/06/9-strong-buy-dividend-aristocrats-to-buy-now-in-case-elon-musk-is-right/ | In the history of the United States, there have been a handful of true visionaries that changed life and the world as we know it. | 9 ‘Strong Buy' Dividend Aristocrats to Buy Now in Case Elon Musk Is Right | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-06-05 14:30:15 | https://marijuanastocks.com/top-medical-cannabis-stocks-to-buy-2-to-watch-for-long-term-investing/ | These Could Be The Best Medical Cannabis Stocks To Watch The post Top Medical Cannabis Stocks To Buy? 2 To Watch For Long Term Investing appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Medical Cannabis Stocks To Buy? 2 To Watch For Long Term Investing | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-05 07:04:00 | https://www.fool.com/investing/2022/06/05/3-great-dividend-stocks-to-buy-in-june/ | Investors should be able to count on recurring income with these stocks. | 3 Great Dividend Stocks to Buy in June | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-05 05:43:00 | https://www.fool.com/investing/2022/06/05/can-the-best-selling-drugs-of-2021-repeat-their-pe/ | These were the industry's bestsellers last year, but how long can they stay on top? | Can the Best-Selling Drugs of 2021 Repeat Their Performance? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-04 11:23:00 | https://www.fool.com/investing/2022/06/04/2-top-dividend-kings-to-buy-for-the-long-haul/ | These two healthcare stocks have delivered ever higher dividends to their shareholders for decades. | 2 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-06-03 18:25:40 | https://www.youtube.com/watch?v=HC50mw-M9r8 | Joanne Feeney, Advisors Capital Management partner and portfolio manager, joins ‘Closing Bell: Overtime' to discuss some of her top names for investors' portfolios in the current environment. | Two-minute drill: TJX, CIEN & ABBV | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-06-03 11:45:00 | https://www.fool.com/investing/2022/06/03/3-reasons-to-buy-this-blue-chip-stock/ | 2022 has been characterized by a paradigm shift from growth stocks to dividend stocks. | 3 Reasons to Buy This Blue-Chip Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-06-03 10:32:09 | https://www.zacks.com/stock/news/1933547/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-29 07:31:00 | https://www.fool.com/investing/2022/05/29/3-dividend-stocks-you-can-buy-and-hold-forever/ | Their strong underlying businesses should keep the quarterly payouts flowing to shareholders. | 3 Dividend Stocks You Can Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Finbold | 2022-05-27 06:38:35 | https://finbold.com/two-large-cap-pharmaceutical-stocks-with-a-solid-dividend-yield/?SNAPI | With healthcare costs rising in the U.S., it seems as if the new drugs will have to follow suit. Big. | Two large-cap pharmaceutical stocks with a solid dividend yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-26 18:00:22 | https://investorplace.com/2022/05/7-high-yield-retirement-stocks-to-buy-for-your-nest-egg/ | These 7 high-yield retirement stocks to buy are among a list of companies that are dividend aristocrats and offer great dividends. The post 7 High-Yield Retirement Stocks to Buy for Your Nest Egg appeared first on InvestorPlace. | 7 High-Yield Retirement Stocks to Buy for Your Nest Egg | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-05-26 12:30:00 | https://stockmarket.com/featured/best-health-care-stocks-to-invest-in-2022-3-names-to-watch-2022-05-26 | Here are 3 top health care stocks to watch in the stock market right now. | Best Health Care Stocks To Invest In 2022? 3 Names To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-26 10:41:13 | https://investorplace.com/2022/05/7-ideal-dividend-stocks-to-buy-for-a-rich-retirement/ | These dividend stocks to buy will enable you to offset your portfolio risk. The post 7 Ideal Dividend Stocks to Buy for a Rich Retirement appeared first on InvestorPlace. | 7 Ideal Dividend Stocks to Buy for a Rich Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-26 06:00:00 | https://www.fool.com/investing/2022/05/26/3-healthcare-stocks-to-hold-for-10-years/ | They're leaders in their fields. | 3 Healthcare Stocks You Can Buy and Hold for the Next Decade | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-05-25 13:37:02 | https://seekingalpha.com/article/4514441-bristol-myers-squibb-abbvie-who-fits-barbell | Both Bristol Myers Squibb and AbbVie spark interest for income- and value-oriented investors. You will see why we favor AbbVie as a better fit for our barbell strategy to build an enduring portfolio for an early retirement. | Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-25 11:00:00 | https://www.fool.com/investing/2022/05/25/2-dividend-kings-that-are-soundly-beating-the-mark/ | These stocks could be good places to park your money. | 2 Dividend Kings That Are Soundly Beating the Market in 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-24 10:00:00 | https://www.fool.com/investing/2022/05/24/these-2-numbers-could-spell-trouble-for-abbvie-sto/ | The next few quarters could be a bumpy ride. | These 2 Numbers Could Spell Trouble for AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-05-23 17:15:12 | https://www.gurufocus.com/news/1725078/fund-managers-dump-berkshire-abbvie-in-1st-quarter | The first quarter of 2022 has signaled an end to the monetary policy-driven bull market that lasted from the Covid-19 market crash in March 2020 all the way through the end of 2021. The combination of low interest rates, heavy money-printing and easy access to corporate debt has finally made its way through the economy... | Fund Managers Dump Berkshire, AbbVie in 1st Quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-21 11:00:44 | https://investorplace.com/2022/05/7-quality-dividend-stocks-to-buy-on-the-dip/ | While the current market environment is full of uncertainty, these dividend stocks to buy offer a hedge against the rampant inflation rates. The post 7 Quality Dividend Stocks to Buy on the Dip appeared first on InvestorPlace. | 7 Quality Dividend Stocks to Buy on the Dip | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-21 07:31:40 | https://investorplace.com/2022/05/7-retirement-stocks-to-buy-for-any-market-conditions/ | Although the recent market choppiness has many folks worried, you can still depend on these relevant retirement stocks to buy. The post 7 Retirement Stocks to Buy for Any Market Conditions appeared first on InvestorPlace. | 7 Retirement Stocks to Buy for Any Market Conditions | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-05-20 13:55:56 | https://www.youtube.com/watch?v=adZ3uJU1HXA | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Deere, Abbvie, Costco & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-05-20 10:32:22 | https://www.zacks.com/stock/news/1927031/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-19 12:00:44 | https://investorplace.com/2022/05/6-stocks-to-buy-to-hedge-your-portfolio-with-stable-dividends-and-low-pes/ | These six stocks to buy will help you hedge your portfolio through their dividend yields and low P/E valuations. The post 6 Stocks to Buy to Hedge Your Portfolio in a Down Market appeared first on InvestorPlace. | 6 Stocks to Buy to Hedge Your Portfolio in a Down Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-19 06:40:00 | https://www.fool.com/investing/2022/05/19/these-3-stocks-have-doubled-over-the-past-3-years/ | These three solid companies have the financial strength to drive their shares higher. | These 3 Stocks Have Doubled Over the Past 3 Years. Can They Do It Again? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-18 18:16:18 | https://investorplace.com/2022/05/7-best-value-stocks-to-buy-if-you-need-some-market-stability-in-your-life/ | Finding the best value stocks is a matter of understanding which companies have solid short-term and long-term prospects. These 7 have both. | 7 Best Value Stocks to Buy if You Need Some Market Stability in Your Life | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-17 11:23:00 | https://www.fool.com/investing/2022/05/17/is-it-too-late-to-buy-abbvie-stock/ | The bears think it's time to take profits and leave. But are they right? | Is It Too Late to Buy AbbVie Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-05-17 10:32:22 | https://www.zacks.com/stock/news/1925373/abbvie-abbv-buys-option-rights-to-nextgen-inflammation-drug | AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene | AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-16 09:13:00 | https://www.fool.com/investing/2022/05/16/3-dividend-stocks-that-should-pay-you-for-the-rest/ | Even the most aggressive, high-risk investment approach can benefit from passive income. | 3 Dividend Stocks That Should Pay You for the Rest of Your Life | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-16 07:00:18 | https://investorplace.com/2022/05/the-5-best-dividend-stocks-to-buy-now/ | Investors are switching from high-growth shares to the best dividend stocks to help them through the stock market uncertainty The post The 5 Best Dividend Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in sav... | The 5 Best Dividend Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-16 06:00:57 | https://investorplace.com/2022/05/7-retirement-stocks-for-steady-long-term-income-growth/ | Investors looking for retirement stocks should look for companies with high growth and steady income and shun risky, unproven stocks. The post 7 Retirement Stocks for Steady Long-Term Income Growth appeared first on InvestorPlace. | 7 Retirement Stocks for Steady Long-Term Income Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-05-16 03:01:04 | https://www.marketbeat.com/originals/volatile-times-are-when-abbvie-shines-the-brightest/?SNAPI | Even in a slower growth environment, investors who invest in AbbVie (NYSE:ABBV) stock can count on a generous dividend that will add to the stock's total return | Volatile Times Are When AbbVie Shines the Brightest | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-14 10:30:00 | https://www.fool.com/investing/2022/05/14/3-supercharged-dividend-stocks-to-buy-in-the/ | Dividend stocks are a safe haven for investors in a period of market turmoil. | 3 Supercharged Dividend Stocks to Buy in the Stock Market Sell-Off | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-13 05:52:00 | https://www.fool.com/investing/2022/05/13/3-dividend-stocks-you-can-buy-and-hold-for-decades/ | You can really think long term with these great dividend stocks. | 3 Dividend Stocks You Can Buy and Hold for Decades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-05-12 15:48:03 | https://www.zacks.com/stock/news/1923567/abbvie-s-abbv-rinvoq-meets-crohn-s-disease-study-goals | AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease. | AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-05-08 09:00:00 | https://seekingalpha.com/article/4507891-abbvie-buy-hold-or-sell-after-q1-results | AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff. | AbbVie: Buy, Hold, Or Sell After Q1 Results? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-05-06 07:33:52 | https://investorplace.com/2022/05/7-defensive-healthcare-stocks-to-buy-now/ | As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace. | 7 Defensive Dividend Healthcare Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-05 05:52:00 | https://www.fool.com/investing/2022/05/05/this-stock-is-trouncing-the-market-in-2022-and-its/ | The big biotech's winning ways are likely to continue. | This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-05-04 05:52:00 | https://www.fool.com/investing/2022/05/04/warren-buffett-dividend-stocks-passive-income/ | You'll need to invest $100,000 in each stock to generate five-figure annual income. | These Warren Buffett Dividend Stocks Can Make You $12,800 in Passive Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-05-02 09:52:50 | https://247wallst.com/investing/2022/05/02/8-dividend-aristocrat-leaders-to-buy-now-with-the-stock-market-ready-to-blow-up/ | The writing is on the wall, and veteran investors know it. Any time you have an almost a 1,000 point move in the venerable Dow Jones industrial average and give it all back the next day like we did late last week, it indicates that fund managers are selling every uptick, and savvy hedge fund portfolio managers are tryi... | 8 Dividend Aristocrat Leaders to Buy Now With the Stock Market Ready to Blow Up | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-05-01 17:00:56 | https://marijuanastocks.com/the-best-marijuana-stocks-in-2022-and-the-different-cannabis-sectors-to-watch-right-now/ | The Cannabis Industry And Parts Of The Sector To Watch In 2022 The post The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-30 16:32:58 | https://seekingalpha.com/article/4505567-abbvie-q122-results-dampen-enthusiasm-and-test-managements-growth-plans | AbbVie reported Q122 earnings last night, and there was good and bad news - the bad led to a share price drop of ~10%. Revenues came in a little lower than Street expectations, at $13.54bn, and FY22 EPS was downgraded from $14.00 - $14.20 to $13.92 - $14.12. | AbbVie: Q122 Results Dampen Enthusiasm & Test Management's Growth Plans | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-30 11:00:00 | https://www.fool.com/investing/2022/04/30/want-2000-passive-income-invest-10000-stock/ | This dividend stock is one of the few holdings that Cathie Wood and Warren Buffett have in common. | Want $2,000 in Passive Income? Invest $10,000 in This Cathie Wood Dividend Stock and Wait 5 Years | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-30 05:57:00 | https://www.fool.com/investing/2022/04/30/abbvies-q1-good-news-that-investors-could-be-missi/ | The big drugmaker's results were disappointing, but there were several things to like in its report. | AbbVie's Q1 Good News That Investors Could Be Missing | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-04-29 16:46:30 | https://www.fool.com/investing/2022/04/29/why-abbvies-shares-dropped-105-friday/ | Some of the pharmaceutical company's sales trends concerned investors. | Why AbbVie's Shares Dropped 10.5% Friday | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-04-29 15:22:24 | https://www.youtube.com/watch?v=3qetXLrZPAk | Mohit Bansal, Wells Fargo Securities senior equity analyst, joins 'Power Lunch' to discuss biopharma and the market. | Biopharma can perform well in recession based on past data, says Wells Fargo's Mohit Bansal | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-29 12:48:18 | https://www.zacks.com/stock/news/1912136/abbvie-abbv-q1-earnings-top-competition-rises-for-imbruvica | AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. | AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-04-29 12:29:33 | https://www.gurufocus.com/news/1699463/a-trio-of-stocks-beating-the-sp-500 | Shareholders of Nokia Oyj ( NOK , Financial), AbbVie Inc. ( ABBV , Financial) and Microsoft Corp. ( MSFT , Financial) saw the value of their shares increase significantly over the past year, outperforming the S&P 500 Index. The benchmark index for the U.S. market stands at $4,287.50 as of April 28, having gained 1% ove... | A Trio of Stocks Beating the S&P 500 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-04-29 11:20:02 | https://seekingalpha.com/article/4505115-abbvie-inc-abbv-ceo-rick-gonzalez-on-q1-2022-results-earnings-call-transcript | AbbVie Inc. (NYSE:ABBV ) Q1 2022 Earnings Conference Call April 29, 2022 9:00 AM ET Company Participants Liz Shea - Vice President, Head of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Tom Hudson - Senior Vice Presi... | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q1 2022 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-29 10:32:26 | https://www.zacks.com/stock/news/1911511/abbvie-abbv-tops-q1-earnings-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Tops Q1 Earnings Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2022-04-29 10:02:00 | https://www.barrons.com/articles/abbvie-stock-earnings-guidance-humira-arthritis-51651240769 | The company's mega-blockbuster Humira—used to treat rheumatoid arthritis—will face competition from so-called biosimilars in the U.S. next year. | AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-04-29 09:55:05 | https://www.benzinga.com/general/biotech/22/04/26895813/abbvie-shares-fall-on-mixed-bag-q1-results-cuts-fy22-profit-guidance | AbbVie Inc (NYSE: ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. | AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-04-29 08:07:11 | https://www.marketwatch.com/story/abbvies-stock-is-down-3-after-missing-on-revenue-in-the-first-quarter-of-2022-2022-04-29 | Shares of AbbVie Inc. ABBV, -0.83% were down 3.4% in premarket trading on Friday after the company missed on revenue in the first quarter of the year. AbbVie had earnings of $4.5 billion, or $2.51 per share, in the first quarter of 2022, up from $3.5 billion, or $1.99 per share, in the same quarter of 2021. | AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2022-04-29 07:49:00 | https://www.reuters.com/article/abbvie-results/abbvie-misses-quarterly-sales-estimates-as-humira-rivals-bite-idUSKCN2ML0YE | AbbVie Inc missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq. | AbbVie misses quarterly sales estimates as Humira rivals bite | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2022-04-28 15:49:00 | https://www.barrons.com/articles/big-pharma-stocks-defensive-buy-51651175275 | The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets. | Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-28 12:02:09 | https://www.zacks.com/stock/news/1910199/drug-biotech-stocks-q1-earnings-due-on-apr-29-bmy-abbv-azn | Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29. | Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-04-28 11:22:27 | https://www.zacks.com/stock/news/1910182/why-earnings-season-could-be-great-for-abbvie-abbv | AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | Why Earnings Season Could Be Great for AbbVie (ABBV) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.